Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Mai 2023 16:00 ET | Quelle: Dyadic International, Inc.

Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic One Health (“Rubic”) to develop,...
14. April 2022 17:00 ET | Quelle: Endominance, Inc.

Endominance Launches Exciting New Microbiome, Anxiety, and Cognitive Orientation Study

IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Endominance, Inc., a leading cognitive assessment and data collection firm headquartered in Virginia, today announced the launch of a...
20. Januar 2022 08:30 ET | Quelle: Dyadic International, Inc.

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
15. Juli 2019 09:30 ET | Quelle: Processa Pharmaceuticals, Inc.

PROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499

HANOVER, MD, July 15, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
09. Januar 2019 09:00 ET | Quelle: Processa Pharmaceuticals, Inc.

PROCESSA PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499 DATA AT THE ANNUAL MEETING OF AMERICAN ACADEMY OF DERMATOLOGY

HANOVER, MD, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...